Business
BioSenic : announces partnership with 4Moving Biotech and secures its financing.
BioSenic : announces partnership with 4Moving Biotech and secures its
About this update from Biosenic
[{"type":"text","content":"\n \n BioSenic announces partnership with 4Moving Biotech to join forces to co-develop 4P004v, first-in-class GLP-1-based disease modifying drug for post-ligament surgery in dogs and the securing of its financing for the coming months by means of an amendment to its convertible bonds agreement\n \n \n \n BioSenic and 4Moving Biotech enter into binding co-development agreement dedicated to developing first-in-class therapies targeting the progression of knee osteoarthritis\n \n \n \n Biosenic and Global Tech Opportunities 15 (\"GTO 15\") have entered into an amendment to the convertible bonds (\"CB\") agreement securing a further EUR 2 million of the program, including thirteen tranches of EUR 150,000 each and a last tranche of EUR 50,000\n \n \n \n Mont-Saint-Guibert, Belgium, 1 July 2025 at 7:30 PM - BIOSENIC (Euronext Brussels and Paris: BIOS) announces1 (i) the signing of a binding co-development agreementi with 4Moving Biotech (4MB), a French clinical-stage company developing first-in-class therapies targeting the progression of knee osteoarthritis in humans and (ii) the securing of its financing for the next 14 months by means of an amendment to the convertible bonds agreement with GTO 15 allowing it to draw up to a further EUR 2 million, including thirteen tranches of EUR 150,000 each and a last tranche of EUR 50,000, without any liquidity conditions until the new 9th tranche.\n BioSenic and 4MB will join forces in a co-risk, co-shared development program (\"CCD\") targeting post-ligament surgery (PLS) recovery in dogs, a significant unmet need in companion animal orthopedics. The collaboration aims to demonstrate clinical proof-of-concept in dogs undergoing post-operative recovery after ligament repair. With its unique anti-inflammatory and anti-catabolic and regenerative action, 4P004 is positioned as a potential first-in-class in veterinary orthopedics.\n \n \n 4P004 is a GLP-1 analog tailored for intra-articular use in knee osteoarthritis. It was developed to exploit the analgesic, anti-inflammatory, anti-catabolic, and anabolic benefits of GLP-1. Preclinical studies suggest that 4P004 may slow disease progression and improve joint function by modulating the biological pathways throughout all joint tissues. This positions 4P004 as a disease-modifying treatment candidate that could significantly improve patient outcomes...